A Prospective, Single-Blind, Multicenter, Randomized Controlled Study to Evaluate the Clinical Equivalence of two Triclosan-Coated Polyglactin 910 Sutures, Trusynth Plus Neo and Vicryl Plus in Caesarean Section Wound Closure - NIL

Start Date25 Mar 2026

Sponsor / Collaborator

Healthium Medtech Ltd.

NCT07814898

/ CompletedPhase 4IIT

Comparison Between the Effect of Triclosan Toothpaste and Chlorhexidine Mouthwash on Gingival Health in a Group of Fixed Orthodontic Patients: A Randomized Controlled Clinical Trial

Study Protocol Introduction Title of the research study Comparison Between the effect of Triclosan Toothpaste and chlorhexidine Mouthwash on Gingival Health in Fixed Orthodontic Patients :A randomization controlled clinical trial.
Background Orthodontic brackets and elastics might interfere with effective removal of dental plaque, thereby increasing the risk of gingivitis. The aim of this study to compare the effect of triclosan toothpaste and chlorhexidine mouthwash on gingival health in a group of fixed orthodontic patients.
Procedures Participant eligibility will be assessed based on a dental examination, medical history and inclusion and exclusion criteria.
Inclusion criteria:
* Patient age 18-35 years old.
* Orthodontic patient in leveling and alignment stage.
* Interested, cooperative fixed orthodontic patients who are aware of the importance of using toothpastes and mouthwash during orthodontic treatment.
* Patients who have good oral hygiene during orthodontic treatment.
* Medically fit patients who are not using any medical treatment that may affect periodontal health such as (antibiotic, phenytoin).
* Class I, II, III malocclusion with mild to moderate crowding.
Exclusion criteria:
* Patients with systemic disease affecting periodontal health such as (lichen planus, pemphigus)
* Smoker patients.
* Chewing qat patients. Eligible participants will be randomly assigned to one of three groups Group 1: will use Colgate Total® toothpaste containing sodium fluoride 0.24% and Triclosan 0.3% for one month twice a day.
Group 2: will use Maxfresh ® toothpaste containing sodium fluoride 0.24% in addition to Hexadyl® Chlorhexidine mouthwash for one month twice a day.
Group 3: will brush their teeth by Colgate Maxfresh ® toothpaste containing sodium fluoride 0.24% for 3 month twice a day.
The participant will be instructed to brush and rinse his or her teeth twice a day and they must follow orthodontic treatment instructions to maintain the braces.
The study will last for three month.

Start Date14 Feb 2026

Sponsor / Collaborator-

CTRI/2026/01/100177

/ Not yet recruitingNot ApplicableIIT

Comparative evaluation of the antiplaque efficacy of two herbal toothpastes and a triclosan toothpaste on patients undergoing orthodontic treatment. - NIL

Start Date15 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Triclosan

100 Translational Medicine associated with Triclosan

100 Patents (Medical) associated with Triclosan

5,926

Literatures (Medical) associated with Triclosan

01 Jan 2027·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Simultaneous voltammetric determination of triclosan and chlorhexidine in pharmaceutical and personal care products at glassy carbon electrode

Article

Author: Bajer, Tomáš ; Kašpar, Michal ; Mikysek, Tomáš ; Sýs, Milan ; Bártová, Michaela

Although a number of electroanalytical methods for the determination of triclosan (TCS) and chlorhexidine (CHX) have been reported to date, none has been developed for their simultaneous determination. The present work describes the first electroanalytical method for their simultaneous voltammetric determination in pharmaceutical and personal care products. The method is based on the anodic oxidation of these antimicrobial agents at a glassy carbon electrode in a mixture of 0.1 mol L^-1 acetate buffer (pH 4) and 99.8% ethanol in an 8:2 ratio, using differential pulse voltammetry. At optimum working conditions, the current responses could be calibrated within a linear range of 5-50 µmol L^-1, with sensitivities of 0.026 µA L µmol^-1 for TCS and 0.018 µA L µmol^-1 for CHX, quantification limit of 4.6 µmol L^-1 for TCS and 5.8 µmol L^-1 for CHX, and detection limit of 1.4 µmol L^-1 for TCS and 1.8 µmol L^-1 for CHX. A satisfactory precision, characterised by a relative standard deviation of 4%, was achieved. Negligible interference from accompanying substances allows the use of the calibration-curve method, while a statistically insignificant y‑intercept enables the application of the multiple standard-addition method. The validation performed by the analysis of a model sample, a toothpaste and a mouthwash provided results comparable to those obtained by reference reversed-phase HPLC with spectrophotometric detection and gas chromatography with mass spectrometry. The results were statistically comparable according to Horn's test, thus confirming the practical applicability of the developed voltammetric method in pharmaceutical safety control.

01 Dec 2026·BRAZILIAN JOURNAL OF MICROBIOLOGY

Pharmacological potential of the marine peptide cyclo(L-phenylalanyl-L-prolyl) against both multidrug-resistant, gram-negative Acinetobacter baumannii and gram-positive Staphylococcus aureus: structure – activity relationship, computational and experimental studies

Article

Author: Vadivel, Meyappan ; Kumar, Udit ; Nayak, Subhashree Subhasmita ; Sakthivel, Natarajan ; Shankar, Sriram

The marine cyclic dipeptide, cyclo(phenylalanine-proline) (cFP), exhibits promising antimicrobial and antibiofilm activities. The balanced reactivity and stability of the compound, which are conducive to multi-target interactions, were identified using the density functional theory (DFT) calculations, and PASS (Prediction of Activity Spectra for Substances) analysis predicted cFP's antimicrobial activity based on its structure-activity relationship. Antibacterial efficacy was determined by MIC and MBC with values of 200-250 µg/mL and 400-500 µg/mL, respectively, against Acinetobacter baumannii and Staphylococcus aureus. Time-kill kinetics demonstrated bacteriostatic effects at sub-MIC concentrations, and bactericidal activity at higher concentrations, with 3D growth curves suggesting dose-dependent inhibition. The cFP mildly elevates intracellular reactive oxygen species (ROS), depletes the antioxidant glutathione, and, through ROS generation, only partially attenuated by N-acetylcysteine scavenging, indicating that redox perturbation contributes to, but does not solely account for, its antimicrobial activity. The cFP demonstrated potent antibiofilm potential, achieving a 79.3% reduction in mature biofilm biomass at 100 µg/mL, with marked fragmentation observed microscopically at sub-MIC doses. Extracellular polymeric substance (EPS) production was inhibited dose-dependently, exceeding 60% suppression at the highest concentrations. Furthermore, cFP significantly reduced bacterial cell surface hydrophobicity, thereby impairing adhesion mechanisms critical for biofilm formation. Molecular docking and 100 ns MD simulations suggest that cFP can form stable interactions with virulence-associated proteins, including FabI, AceR, GyrB, and SarA, which are established antibacterial or antivirulence targets with known reference ligands such as triclosan, chlorhexidine, novobiocin, and 2-[(methylamino)methyl]phenol, respectively. The cFP exhibited strong hemocompatibility with minimal hemolytic activity (< 5%), indicating low erythrocyte membrane toxicity. Taken together, the experimental and computational findings suggest that cFP is a promising antimicrobial lead and warrant further mechanistic and translational investigation.

01 Dec 2026·FOOD AND CHEMICAL TOXICOLOGY

Associations of bisphenol A, F and triclosan with serum lipids: the mediating effect of inflammation and oxidative stress

Article

Author: Zhong, Rong ; Qiu, Weihong ; He, Heng ; Cheng, Liming ; Zeng, Qiang ; Tian, Jianbo ; Zhang, Shanshan ; Miao, Xiaoping ; Shen, Na ; Chang, Jiang ; Zhu, Ying ; Liu, Huan

BACKGROUND:

Environmental phenolic compounds have been associated with serum lipids. However, the underlying mechanisms remain unclear.

METHODS:

We investigated 792 adults from Tongji Hospital in Wuhan. Linear regression models were used to quantify relationships among urinary bisphenol A (BPA), F (BPF), triclosan (TCS), inflammation response (white blood cell [WBC] count) and oxidative stress markers, and serum lipids. Bayesian Kernel Machine Regression (BKMR) was performed to evaluate the combined association of phenolic compounds on serum lipids. Bootstrapped mediation analysis was conducted to investigate the role of inflammation and oxidative stress markers.

RESULTS:

Linear regression models showed urinary BPA (β = -0.017, 95% CI = -0.030∼-0.004) and BPF (β = -0.014, 95% CI = -0.024∼-0.003) were inversely associated with high-density lipoprotein cholesterol (HDL-C). BKMR single-exposure analyses revealed BPA was inversely associated with triglycerides, while BPF was positively associated with triglycerides and inversely associated with HDL-C. Urinary BPA, BPF and TCS were associated with oxidative stress markers. Urinary BPF was associated with total WBC, lymphocyte, monocyte, and eosinophil counts. BPF showed significant mediating effects on triglycerides and HDL-C through WBC, lymphocytes, monocytes, and eosinophils counts, with mediation proportions ranging from 11.30% to 40.29%.

CONCLUSIONS:

BPF showed significant indirect effects on both HDL-C and triglycerides through inflammation response.

News (Medical) associated with Triclosan

23 Jul 2025

·www.einpresswire.com

Topical Antiseptic Products: Hand Sanitizers and Antibacterial Soaps

FDA is undertaking a review of active ingredients used in a variety of over-the-counter (OTC) antiseptic rubs and wash products. Health care antiseptics are being evaluated separately from consumer antiseptics because they have different proposed use settings and target populations, and the risks for infection in the different settings varies. More information about both is presented below. What are antiseptics? Over-the-counter consumer antiseptics can generally be broken down into two groups: washes and rubs. The definition for each is below. Washes Antiseptic wash products, also known as antibacterial soaps, are intended for use with water and are rinsed off after use, and include hand washes /soaps and body washes. FDA supports the CDC’s recommendation to use plain soap and water to wash your hands. When water is not readily available, a hand sanitizer may be a suitable alternative. Rubs Rubs are leave-on products, or hand “sanitizers,” as well as antiseptic wipes. These products are intended to be used when soap and water are not available, and are left on and not rinsed off with water. Remember: Just like with all over-the-counter drugs, it is important to read the label every time you use hand sanitizers or antiseptic wipes. These products should be stored out of the reach of children and should be used with adult supervision. Use hand sanitizers and antiseptic wipes only as directed on the label. Do not swallow them. If you swallow these products call a poison control center immediately. What is the difference between health care antiseptics and consumer antiseptics? Health Care Antiseptics Health care antiseptics differ from consumer antiseptics in the following ways: They are primarily used by health care professionals in hospitals, clinics, doctors’ offices, outpatient settings and nursing homes. Health care antiseptics are not only used to protect the user but also to protect the patient, whereas consumer antiseptics are generally applied to protect the user. Health care antiseptics are often used more frequently by health care workers than consumers use consumer antiseptics. Consumer Antiseptics Consumer antiseptics differ from healthcare antiseptics in the following ways: Consumer antiseptics are primarily used in the home, schools, daycares or other public settings. Most consumer antiseptics are sold in retail establishments like drug stores and grocery stores. How are health care and consumer antiseptics being evaluated? FDA compares the risks and the benefits for active ingredients under specified conditions of their use to help determine whether that active ingredient is generally recognized as safe and effective (GRASE). Since FDA’s 1994 evaluation of OTC antiseptics, many things have changed, including the frequency of use of some products, new technology that can detect low levels of antiseptics in the body, FDA’s safety standards, and scientific knowledge about the impact of widespread use. FDA’s current effort is designed to ensure that the safety and effectiveness evaluations and determinations for active ingredients used in antiseptics are consistent, up-to-date, and appropriately reflect current scientific knowledge and increasing use patterns. Safety FDA proposed that data was needed from a standard battery of tests that is used to determine the safety of many drugs, including OTC antiseptics. This array of tests has changed over time to incorporate improvements in safety testing. For more specific information on safety tests, please see the final rule on consumer antiseptic washes , the final rule on health care antiseptics , and the final rule on consumer antiseptic rubs . Efficacy For consumer antiseptic washes , millions of Americans use antiseptic hand soaps and body washes each day, but these products have not yet been shown to be more effective at preventing illness than plain soap and water. Additionally, emerging data have raised concerns that long-term, daily use of these products may outweigh their presumed benefits. The clinical studies data on effectiveness would specifically need to demonstrate that the active ingredients in consumer antiseptic wash products are superior to non-antibacterial soap in preventing illness or reducing infection. FDA has issued a final rule requiring the removal of certain active ingredients from OTC consumer antibacterial hand soaps and body washes including the most commonly used triclosan and triclocarban. Antibacterial manufacturers did not provide the necessary data to demonstrate the effectiveness for these active ingredients and so the FDA could not determine that they are generally recognized as safe and effective for use in consumer antiseptic washes. For more specific information on effectiveness testings for active ingredients used in consumer antiseptic washes, please see the final rule on consumer antiseptic washes . FDA is not proposing clinical outcome studies for active ingredients when used in health care antiseptics or in consumer antiseptic rub products. FDA is requiring clinical simulation studies for health care antiseptics because of ethical concerns with conducting studies in the health care setting; FDA is requiring the clinical simulation studies for consumer antiseptic rubs because these products are intended for use when soap and water are not available, and so they need not demonstrate clinical effectiveness compared to soap and water. For specific information on the efficacy data requested for health care antiseptics and consumer antiseptic rubs, please see the final rules on health care antiseptics and final rule on consumer antiseptic rubs and their respective dockets. Regulatory Information More information Health care antiseptics Content current as of: 06/18/2020 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

16 Jun 2025

·www.prnewswire.com

CodeSteri Launches PlaDeo: The World's First Bio-Plasma Powered Deodorant Device

A Breakthrough in Underarm Odor Control and Axillary Bromhidrosis Treatment SEOUL, South Korea, June 16, 2025 /PRNewswire/ -- CodeSteri Inc., a tech-driven startup based at the Hanyang University College of Medicine in Seoul, today announced the launch of PlaDeo, the world's first electronic deodorant device powered by bio-plasma. Designed to eliminate underarm odor safely and effectively, PlaDeo offers a revolutionary approach to managing axillary bromhidrosis—a medical condition characterized by chronic underarm odor—without the use of chemicals, pore-blocking agents, or aluminum salts. Continue Reading In 2020, PlaDeo—then branded Pragrant—was awarded the CES Innovation Award in the Health & Wellness category, recognizing its disruptive potential in personal care technology. Unlike conventional deodorants that mask odor using synthetic fragrances or suppress sweat glands, PlaDeo employs reactive oxygen species (ROS)—including hydroxyl radicals (OH⁻) and superoxide ions (O₂⁻)—to directly neutralize odor-causing bacteria and molecular residues on the skin. This plasma-powered mechanism ensures a non-toxic, non-residue, and skin-safe experience for daily users. Scientifically Validated Performance PlaDeo's efficacy has been scientifically proven. A peer-reviewed study published in Scientific Reports (2024), along with a clinical trial conducted at Hanyang University Hospital, demonstrated that 94% of participants experienced significant odor reduction after using the device regularly. These results validate PlaDeo as not only a hygiene product, but also a clinically relevant solution for those suffering from persistent body odor. The launch of PlaDeo comes at a time when global consumers are actively seeking chemical-free, science-supported alternatives for personal hygiene. With increasing awareness of the long-term risks posed by ingredients such as triclosan and aluminum compounds, PlaDeo addresses a growing demand for effective, health-conscious innovation in the deodorant market. Its compact, travel-friendly form factor also makes it ideal for use in gyms, offices, eldercare environments, and hospitals—anywhere discretion and hygiene intersect. Key Features: CES Award-Winning Plasma Technology: Kills bacteria and neutralizes odor at the source. Clinically Proven: Scientifically validated by peer-reviewed studies and human trials. Chemical-Free and Skin-Friendly: No residue, no irritation—just clean you. Portable and Easy to Use: Compact design for daily personal or medical use. PlaDeo is now available for pre-order on Indiegogo. For more details or to back the campaign, visit the official project page at: SOURCE Codesteri WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

15 Sep 2022

·www.globenewswire.com

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. The study is a double-blind, randomized, placebo-controlled trial evaluating the safety and antiviral activity of a single dose of zotatifin and is being conducted in collaboration with the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency. Dose escalation to the second cohort comes after the positive recommendation of the independent data safety monitoring board upon review of safety data from the first dose cohort. The completed cohort also included the first subjects dosed with a sub-cutaneous formulation of zotatifin and preliminary analysis demonstrated equivalent plasma drug levels compared to IV delivery. “As much as we all want to move past the COVID-19 pandemic, the virus has continued to evolve and there remains a need for well tolerated and effective antiviral medicines that can be easily accessed by vulnerable populations to prevent severe disease, hospitalization and death,” said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. “Administered as a single dose injection, zotatifin aligns with the Test to Treat initiative being promoted by the U.S. government and has the potential to overcome many of the limitations of existing treatment options, including poor treatment adherence that can result in viral rebound. Achieving equivalent drug levels when zotatifin was delivered by the sub-cutaneous route provides an opportunity for convenient dosing in both the COVID and cancer settings.” Zotatifin is a potent and sequence-selective small molecule inhibitor of eIF4A, a host protein required to unwind the complex secondary structures within the 5’ untranslated region of the genome of SARS-CoV-2 and other RNA viruses. Inhibiting the activity of eIF4A prevents the translation of the viral polyprotein needed for replication of the virus. Zotatifin was identified as a potent anti-SARS-CoV-2 agent in a study conducted by the international research consortium QBI Coronavirus Research Group (QCRG), led by Nevan Krogan, and previously published in Nature. Zotatifin is a host-directed investigational therapeutic, meaning that it acts on a human protein that the SARS-CoV-2 virus hijacks to synthesize new viruses. As such, zotatifin may have a higher barrier to viral mutational escape than therapies that target components of the virus itself. “If clinical results continue to demonstrate what we have observed in preclinical studies, zotatifin could have utility both in the treatment of COVID-19 – and diseases caused by other coronaviruses – as a monotherapy or in combination with other medicines,” continued Dr. Worland. “It has the added potential to be an important tool in the arsenal for future pandemic preparedness.” About Zotatifin Zotatifin is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to suppress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS. We are currently investigating zotatifin in ongoing clinical trials for solid tumors and, in collaboration with the University of California, San Francisco, as a potential host-directed antiviral therapy in patients with mild to moderate COVID-19. About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency. About the Quantitative Biosciences Institute (QBI) The Quantitative Biosciences Institute (QBI) is a University of California organized research unit reporting through the UCSF School of Pharmacy. QBI fosters collaborations across the biomedical and the physical sciences, seeking quantitative methods to address pressing problems in biology and biomedicine. Motivated by problems of human disease, QBI is committed to investigating fundamental biological mechanisms, because ultimately solutions to many diseases have been revealed by unexpected discoveries in the basic sciences. Learn more at qbi.ucsf.edu.

Financial StatementSmall molecular drugCollaboratemRNAPhase 1

100 Deals associated with Triclosan

External Link

KEGG	Wiki	ATC	Drug Bank
D06226	Triclosan	D09AA06 D08AE04	DB08604

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dental Plaque	Phase 3	Spain	Colgate-Palmolive Co.	01 Jun 2007
Gingivitis	Phase 3	Spain	Colgate-Palmolive Co.	01 Jun 2007
Mucositis	Phase 3	Italy	Colgate-Palmolive Co.	01 Jun 2007
Gingival Diseases	Phase 3	United States	Colgate-Palmolive Co.	01 Apr 2007
Gingival Diseases	Phase 3	Israel	Colgate-Palmolive Co.	01 Apr 2007
Chronic Periodontitis	Phase 3	Australia	Colgate-Palmolive Co.	01 May 2006
Stomatitis	Phase 3	United States	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02360995 (CTgov)	Phase 4	Dental Plaque \| Gingivitis	129	Triclosan+fluoride (Total Toothpaste)	jpcersuiau(levyoiipip) = dzahjqhpke tiiivwynwz (pmridvceli, 0.31) View more	-	30 Mar 2016
				stannous fluoride toothpaste+cetylpyridinium chloride (Toothpaste + Mouthwash)	jpcersuiau(levyoiipip) = zaltbysmrc tiiivwynwz (pmridvceli, 0.45) View more
NCT00763256 (CTgov)	Phase 3	Chronic Periodontitis \| Periodontal Diseases	33	triclosan (Active Comparator)	lsukpjegav(dzfhesqrfo) = hcbcqavvvb mlymwdqhvc (fozgpsjzge, 2.2) View more	-	02 Apr 2012
				Placebo (B - Placebo Comparator)	lsukpjegav(dzfhesqrfo) = fcepgznowu mlymwdqhvc (fozgpsjzge, 2.4) View more
NCT00762853 (CTgov)	Phase 3	Dental Plaque	20	Placebo (Fluoride Toothpaste (Placebo))	zsivhgsylp(bwyzolxmmh) = ltwxooosfq skzzmvonin (uymiplvqba, 0)	-	14 Sep 2010
				triclosan (Active Toothpaste)	zsivhgsylp(bwyzolxmmh) = apbifpwieo skzzmvonin (uymiplvqba, 1.2)
NCT01072201 (implantitis, CTgov)	Phase 3	Mucositis	60	Triclosan and Fluoride (Total Toothpaste)	iibzrcowly(evaxnkjqzm) = ugxeafloen zlebemkpjy (iyromofkja, 17.6) View more	-	19 Feb 2010
				Fluoride (Ultrabrite Toothpaste)	iibzrcowly(evaxnkjqzm) = ienyhwllww zlebemkpjy (iyromofkja, 24.6) View more
NCT01024738 (CTgov)	Phase 3	Dental Plaque	22	Fluoride (Fluoride Toothpaste)	mamvsbqdmi(havovmufut) = vctuujpipo gjmggsguba (qiwmjzpdqb, 0.48)	-	03 Dec 2009
				Chlorhexidine Gluconate (Chlorhexidine Oral Rinse)	mamvsbqdmi(havovmufut) = gswxrbreht gjmggsguba (qiwmjzpdqb, 0.36) View more
NCT01014143 (CTgov)	Phase 2	Dental Plaque	26	Fluoride (Fluoride Toothpaste)	hloubagimd(ijzjwecyin) = qtewxfliwz izmwrrfxdd (xvceuxyztm, 0.61)	-	16 Nov 2009
				Chlorhexidine digluconate (Chlorhexidine Oral Rinse)	hloubagimd(ijzjwecyin) = vuexqnayif izmwrrfxdd (xvceuxyztm, 0.59)
NCT03191721 (Pubmed)	Phase 3	Mucositis	102	Dentifrice containing triclosan	llswhsolge(qrxsglrbjn) = ngdgswiefz akihasumfo (ikueugaenh )	Positive	01 Jan 2009
				Sodium fluoride dentifrice	llswhsolge(qrxsglrbjn) = bktisrpwtl akihasumfo (ikueugaenh )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis